Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...
CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, announced today the integration of the ...
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...
- Results showed 100% sensitivity and reduced time to diagnosis by an estimated 65.5%, with potential to improve pathologists’ workflow in a real-world environment -Brazil-based Grupo Oncoclinicas is ...
A team of researchers in Sweden has discovered that an artificial intelligence platform is capable of accurately diagnosing prostate cancer in tissue samples, offering the potential to speed up ...
The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...
In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...
The US Food and Drug Administration (FDA) has authorized marketing of artificial intelligence (AI) software to help pathologists detect prostate cancer. The program, called Paige Prostate, is the ...
A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...
(HealthDay)—Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a higher risk for adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results